Thermo Fisher Scientific Inc., the world leader in serving science, has opened a new biomanufacturing facility in Chelmsford, Massachusetts. The $160 million, 85,000-square-foot facility will help meet growing demand for the biologic materials needed to produce vaccines and breakthrough therapies for cancer and other diseases. This new site is part of Thermo Fisher’s $650 million multi-year investment to expand its bioprocessing production capabilities.

The technologies produced at the Chelmsford site are used in the purification process of developing biotherapeutics and vaccines. These products help save time and reduce costs so that new treatments can reach more patients faster. With the opening of the site in Chelmsford, Thermo Fisher continues to bring its capacity investments online to support customers as they grow and scale.

When fully staffed, the Chelmsford site will employ up to 250 people in roles across manufacturing, engineering, procurement, quality, warehousing, site leadership and more. This site is part of Thermo Fisher’s global bioprocessing supply network that spans across 100 countries and helps ensure critical medicines reach patients. The Thermo Fisher network of sites have enabled more than 12 billion COVID-19 vaccine doses and partnered with customers to supply technology and materials for many currently approved COVID vaccines and therapeutics. Thermo Fisher employs more than 3,500 people in Massachusetts and operates over 15 facilities across the Commonwealth, including its corporate headquarters located in Waltham.